B Zhao

A check on rational drug design: crystal structure of a complex of human immunodeficiency virus type 1 protease with a novel gamma-turn mimetic inhibitor.

R. DesJarlais, E. Winborne, B. Zhao, 1995, Journal of medicinal chemistry.

Binding interactions of human interleukin 5 with its receptor alpha subunit. Large scale production, structural, and functional studies of Drosophila-expressed recombinant proteins.

S. Carr, M. Doyle, Baoguang Zhao, 1995, The Journal of biological chemistry.

Inhibition of human immunodeficiency virus-1 protease by a C2-symmetric phosphinate. Synthesis and crystallographic analysis.

R. DesJarlais, K. Murthy, E. Winborne, 1993, Biochemistry.

Azepanone-based inhibitors of human and rat cathepsin K.

Y. Ru, D. Veber, K. Ward, 2001, Journal of medicinal chemistry.

Cyclic ketone inhibitors of the cysteine protease cathepsin K.

Y. Ru, D. Veber, M. Hemling, 2001, Journal of medicinal chemistry.

Use of papain as a model for the structure-based design of cathepsin K inhibitors: crystal structures of two papain-inhibitor complexes demonstrate binding to S'-subsites.

R. DesJarlais, D. Veber, S. Abdel-Meguid, 1999, Journal of medicinal chemistry.

Structure-based design of cathepsin K inhibitors containing a benzyloxy-substituted benzoyl peptidomimetic.

R. DesJarlais, D. Veber, S. Abdel-Meguid, 1998, Journal of medicinal chemistry.

Human immunodeficiency virus protease ligand specificity conferred by residues outside of the active site cavity.

M. Doyle, C. Debouck, S. Abdel-Meguid, 1996, Biochemistry.

Design of potent and selective human cathepsin K inhibitors that span the active site.

J G Gleason, S. Carr, R. DesJarlais, 1997, Proceedings of the National Academy of Sciences of the United States of America.

Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F

P. Iversen, R. Walgren, B. Zhao, 2013, Blood Cancer Journal.